Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
PaperCitations, authors & open-access status
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 18 citations, 2023 year and gold oa status.
18
Citations
2023
Year
gold
OA Status